Clinical Trial Update: A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD) [Phase 1]

View source ↗

Summary

Immunobrain Checkpoint completed a first-in-human Phase 1 trial of IBC-Ab002 in individuals with early Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• IBC-Ab002

Snippet

Sponsor: Immunobrain Checkpoint | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED